Using bioactivity profiling to support the progression of phenotypic hits

ABOUT THIS WEBINAR
Bioactivity profiling has been traditionally used to assess the selectivity of new drug candidates in the context of target based approaches, where pharmacological selectivity is a key requirement. Phenotypic screening provides hit molecules where the only initial constrain is activity in a functional assay, without placing any limitation on the starting selectivity. Subsequent progression of these hits requires bioactivity profiling tools to pin-point relevant and not relevant activities in order to support candidate optimisation.
What you will learn…
In this webinar, you will learn how to address the optimisation of hits derived from a target-agnostic phenotypic screen, using a strategy based on combining bioactivity profiling and reference compound characterisation. During this webinar, speaker Arsenio Nueda gave an example of a recent case study.
About this case study
In this case study a phenotypic screen was performed using poly I:C / IL-4 stimulated human bronchial epithelial cells interrogated with a 44,974 compound library. This resulted in the identification of 7 representative hits which down regulated TSLP protein and mRNA levels and provided chemistry and biology starting points for new drug discovery opportunities.
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
KEYNOTE SPEAKER
Arsenio Nueda, Head of Molecular Biology at Almirall
The rest of this content is restricted - login or subscribe free to access
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Assays, Cell-based assays, Drug Discovery, miRNAs, Molecular Biology, Molecular Targets, Protein, Screening, Translational Science
Related organisations
Eurofins Discovery
Thank you to everyone that attended today’s webinar. The on-demand webinar will be available for you to watch within the next 24 hours. Should you have any questions, please comment below.
The webinar is now available to watch on demand.